Animal Health Facility

At Deltamune Animal Health, our approach is to design and manufacture products in accordance with GMP principles and under strict quality control procedures at all stages of the manufacturing process to provide our customers with products of superior quality at competitive prices.

Our facility in Zeekoegat, Roodeplaat, provides us with 5000 square meters manufacturing space. This facility provides the production and storage area to produce a vast variety of products ranging from 60 litres up to 2700 litres per batch.

Our capabilities include commercial vaccine production, autogenous vaccine production and a variety of other custom-made products.

Our team consists of highly-skilled bacteriologists, virologists and biotechnologists who have extensive experience in vaccine manufacturing and are all dedicated to maintain accurate schedules to meet critical delivery requirements

Animal Health Facility

At Deltamune Animal Health, our approach is to design and manufacture products in accordance with GMP principles and under strict quality control procedures at all stages of the manufacturing process to provide our customers with products of superior quality at competitive prices.

Our facility in Zeekoegat, Roodeplaat, provides us with 5000 square meters manufacturing space. This facility provides the production and storage area to produce a vast variety of products ranging from 60 litres up to 2700 litres per batch.

Our capabilities include commercial vaccine production, autogenous vaccine production and a variety of other custom-made products.

Our team consists of highly-skilled bacteriologists, virologists and biotechnologists who have extensive experience in vaccine manufacturing and are all dedicated to maintain accurate schedules to meet critical delivery requirements

Vaccine range for the protection of poultry against Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease.

Vaccine range for the protection of poultry against Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease.

Registered Vaccines

Vaccination (immunisation) is a tried and tested method for assisting in the continual fight against disease in animals. At Deltamune Animal health, our mission is to improve the quality of animal health through vaccine production. Deltamune’s vaccine production facility consists of a highly skilled and dedicated production team.

Since 2008, Deltamune manufactures vaccine in a new production facility where we have integrated GMP guidelines into internal procedures improving the degree to which results and products are consistently exceeding expectations. The production process involves modernized equipment that is validated according to GMP principles and every batch undergoes rigorous quality control testing to ensure that it meets GMP standards for safety, efficacy and stability prior to distribution.

Registered Vaccines

Vaccination (immunisation) is a tried and tested method for assisting in the continual fight against disease in animals. At Deltamune Animal health, our mission is to improve the quality of animal health through vaccine production. Deltamune’s vaccine production facility consists of a highly skilled and dedicated production team.

Since 2008, Deltamune manufactures vaccine in a new production facility where we have integrated GMP guidelines into internal procedures improving the degree to which results and products are consistently exceeding expectations. The production process involves modernized equipment that is validated according to GMP principles and every batch undergoes rigorous quality control testing to ensure that it meets GMP standards for safety, efficacy and stability prior to distribution.

Autogenous Vaccines

Autogenous vaccine solutions are provided through veterinarians. From manufacturing to testing and storage, Deltamune provides our clients with complete support and flexibility in the development of vaccines based on client-supplied specifications.

Autogenous vaccines are problem-specific vaccines intended for emergency and/or restricted use (time/locality) and are defined as safe non-spreading products derived from specific pathogens isolated from a specific herd/flock of animals/birds and used under veterinary supervision in that specific herd/flock.

The production of autogenous vaccines on contract is offered as a complex service, starting with the development stage right through to production. The advantage of this is that (should a customer request it) a vaccine can be made in a relatively short time period after our QC department has purified and characterized an isolate.

Our dedication to quality ensures compliance with all applicable regulatory standards

Autogenous Vaccines

Autogenous vaccine solutions are provided through veterinarians. From manufacturing to testing and storage, Deltamune provides our clients with complete support and flexibility in the development of vaccines based on client-supplied specifications.

Autogenous vaccines are problem-specific vaccines intended for emergency and/or restricted use (time/locality) and are defined as safe non-spreading products derived from specific pathogens isolated from a specific herd/flock of animals/birds and used under veterinary supervision in that specific herd/flock.

The production of autogenous vaccines on contract is offered as a complex service, starting with the development stage right through to production. The advantage of this is that (should a customer request it) a vaccine can be made in a relatively short time period after our QC department has purified and characterized an isolate.

Our dedication to quality ensures compliance with all applicable regulatory standards

Contract Manufacturing

Deltamune has the ability to produce a variety of biological products and vaccines for the biopharmaceutical industry, in which it supports all phases of testing, development and manufacturing. This includes contract filling and labelling according to requirements.

Some services range from bulk vaccine and substance manufacturing to lyophilisation.

Manufacturing Capabilities:

  • Manufacturing of culture media and buffers
  • Virus production via cell culture and SPF eggs
  • Production of bacterial antigens
  • Formulation of vaccines
  • Commercial vaccine manufacturing (scale – up to 4 400 bottles per batch)
  • Pilot scale vaccine manufacturing (scale – up to 990 bottles per batch)
  • Labelling and final packaging
  • Contract manufacturing of vaccines and other biological products
  • Integrated freeze-dried vaccine manufacturing
  • Contract filling and labelling of vaccines

Contract Manufacturing

Deltamune has the ability to produce a variety of biological products and vaccines for the biopharmaceutical industry, in which it supports all phases of testing, development and manufacturing. This includes contract filling and labelling according to requirements.

Some services range from bulk vaccine and substance manufacturing to lyophilisation.

Manufacturing Capabilities:

  • Manufacturing of culture media and buffers
  • Virus production via cell culture and SPF eggs
  • Production of bacterial antigens
  • Formulation of vaccines
  • Commercial vaccine manufacturing (scale – up to 4 400 bottles per batch)
  • Pilot scale vaccine manufacturing (scale – up to 990 bottles per batch)
  • Labelling and final packaging
  • Contract manufacturing of vaccines and other biological products
  • Integrated freeze-dried vaccine manufacturing
  • Contract filling and labelling of vaccines

Research & Development

The Deltamune Product Development division is located at Roodeplaat, North-east of Pretoria and focuses on the development and evaluation of new and effective vaccines and diagnostic tests for diseases affecting poultry, ruminants and equines.

The Product Development team consist of the Research and Development unit, the Animal Studies Unit as well as the Diagnostic Development Unit. Deltamune’s team of highly-skilled researchers include, veterinarians, bacteriologists, virologists, molecular biologists and technologists. The team has extensive experience in the development and evaluation of new bacterial, viral and mycoplasma vaccines and diagnostic tests.

The Product Development team’s facilities comprise a number of laboratories and animal facilities, two of which are DAFF-approved containment/biosafety level 3 (BSL-3) facilities. The main BSL-3 Laboratory and the BSL-3 Animal Facility are well-suited and equipped for safe handling of pathogens and genetically-modified organisms requiring biosafety level 3 containment. State-of-the-art insect-free stables and biosafety level 3 isolators allows for the study of vector-borne diseases and in vivo evaluation of vaccine candidates in a range of laboratory and target animals.

Deltamune’s Product Development Division is strategically important in the development and evaluation of new vaccine formulations and diagnostic tests, and is recognised as a centre of excellence for providing biological and testing solutions in production animal health.

Research & Development

The Deltamune Product Development division is located at Roodeplaat, North-east of Pretoria and focuses on the development and evaluation of new and effective vaccines and diagnostic tests for diseases affecting poultry, ruminants and equines.

The Product Development team consist of the Research and Development unit, the Animal Studies Unit as well as the Diagnostic Development Unit. Deltamune’s team of highly-skilled researchers include, veterinarians, bacteriologists, virologists, molecular biologists and technologists. The team has extensive experience in the development and evaluation of new bacterial, viral and mycoplasma vaccines and diagnostic tests.

The Product Development team’s facilities comprise a number of laboratories and animal facilities, two of which are DAFF-approved containment/biosafety level 3 (BSL-3) facilities. The main BSL-3 Laboratory and the BSL-3 Animal Facility are well-suited and equipped for safe handling of pathogens and genetically-modified organisms requiring biosafety level 3 containment. State-of-the-art insect-free stables and biosafety level 3 isolators allows for the study of vector-borne diseases and in vivo evaluation of vaccine candidates in a range of laboratory and target animals.

Deltamune’s Product Development Division is strategically important in the development and evaluation of new vaccine formulations and diagnostic tests, and is recognised as a centre of excellence for providing biological and testing solutions in production animal health.